Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Neurology

CREB binding protein (CREBBP; CBP); E1A binding protein p300 (EP300; p300)

Mouse and cell culture studies suggest CBP and p300 agonists could be useful for improving cognitive function. In cell culture, a small molecule activator of the histone/lysine acetyltransferases CBP and p300 formulated in a carbon nanoparticle penetrated into cells and increased histone acetylation compared with vehicle. In mice, intraperitoneal injection of the nanoparticle-formulated CBP and p300 activator increased neurogenesis, duration of memory and histone acetylation levels in the frontal cortex compared with injection of nanoparticle alone. Next steps include testing the compound in mouse models for neurodegenerative disorders including Alzheimer's disease (AD).

SciBX 6(28); doi:10.1038/scibx.2013.732
Published online July 25, 2013

Patent pending; licensing status undisclosed

Chatterjee, S. et al. J. Neurosci.;
published online June 26, 2013;
doi:10.1523/JNEUROSCI.5772-12.2013
Contact: Anne-Laurence Boutillier, University of Strasbourg, Strasbourg, France
e-mail:
laurette@unistra.fr
Contact: Tapas K. Kundu, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, India
e-mail:
tapas@jncasr.ac.in